🔎 Trials Near Me

Home › Chronic Kidney Disease › NCT06001827

SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study

Recruiting

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Age of at least 18 years
* Referred for creation of a new AVF
* Willing and able to comply with study requirements, communicate with the study team, and attend follow up visits over a period of 36 months

Exclusion Criteria:

* Planned index procedure to revise or repair an existing fistula
* Target artery inner diameter \< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia
* Target vein inner diameter \< 2.0 mm, as measured by ultrasound while the target arm is under tourniquet pressure and anesthesia
* Significant (at least 50%) stenosis at the target vein on the side of surgery (between the planned anastomosis site and the axillary vein), as diagnosed by preoperative ultrasound
* Known central venous stenosis of at least 50% on the side of surgery
* Presence of a stent or a stent graft within the access circuit
* Known or suspected coagulation disorder that, in the opinion of the Investigator, puts too much risk on the patient for AVF creation
* Known or suspected active infection at the time of surgery
* Congestive heart failure NYHA class 4
* Prior steal on the side of surgery;
* Enrolled in another investigational drug, device, or biological study, or was previously enrolled in this study
* Life expectancy less than 12 months
* Expected to undergo kidney transplant surgery within 6 months of enrollment
* Expected to undergo home hemodialysis
* Females of childbearing potential (premenopausal and not surgically sterile) without documented current negative pregnancy test at screening
* Presence of a comorbid condition that, in the opinion of the Investigator, may significantly confound the collection of safety and efficacy data in this study
* Unwillingness or inability to give consent and/or comply with the study follow up schedule
* Any health condition, which in the opinion of the Investigator, would interfere with the safety of the participant or the participant's ability to comply with the study.

About the study

This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.

What is being tested

Sponsor: VenoStent · Participants: 600 · Started: Jan 3, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06001827

Locations in the U.S.

ArizonaAKDHC Bullhead City, Bullhead City
AKDHC Marana Surgery Center, Marana
Arizona Kidney Disease & Hypertension Centers (AKDHC) Phoenix Surgery Center, Phoenix
Banner University Medical Center, Tucson
CaliforniaOrange County Vascular Access Center, Garden Grove
FloridaTallahassee Research Institute, Tallahassee
IndianaLutheran Medical Group, Fort Wayne
KentuckySurgical Associates of Lexington, Lexington
MassachusettsBrigham and Women's Hospital, Boston
MinnesotaMayo Clinic, Rochester
MissouriUniversity of Missouri, Columbia
Saint Louis University, St Louis
Washington University School of Medicine, St Louis
New YorkNorthwell Health, Lake Success
North CarolinaSurgical Specialists of Charlotte, P.A., Charlotte
WakeMed, Raleigh
South CarolinaMUSC Charleston, Charleston
Vascular Care of South Carolina, Columbia
MUSC Black River, Florence
Prisma Health, Greenville
Medical University of South Carolina (MUSC) Orangeburg / Dialysis Access Institute, Orangeburg
Spartanburg Regional Medical Center, Spartanburg
TennesseeJames Eric Gardner, MD, PC, Memphis
TexasSaint David's HealthCare Partnership, L.P., LLP, Austin
A&V Doctors PLLC, El Paso
Houston Methodist Research Institute, Houston
Upper Valley Dialysis Access Center, LLC, Mission
Houston Methodist Research Institute (Sugar Land), Sugar Land

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.